The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study

Detalhes bibliográficos
Autor(a) principal: Silva, Amanda Brito
Data de Publicação: 2021
Outros Autores: Galbraith, Beatriz Bonfadini de Sá, Borges, Camila Lopes Rieke, Costa, Daniel Pereira de Rezende Sarmento, Bines, Danilo, Lopes, Gabriela Carreiro Kubitschek, Bekierman, Hannah Barboza Vianna, Porto, Helena Ferreira Bruzzi, Seabra, Júlia Moraes de Andrade, Santos, Julia Vieira, Cabral , Michel Vladimir de Sousa, Saugo, Pedro Henrique, Andrade , Victor Gonçalves de, Azevedo, Pedro Leite
Tipo de documento: Artigo
Idioma: por
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/19118
Resumo: COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19.
id UNIFEI_c9133ddbc8e8d21c73e5822c0a96d6ba
oai_identifier_str oai:ojs.pkp.sfu.ca:article/19118
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review studyEl uso de Hidroxicloroquina durante la pandemia de COVID-19: un estudio de revisión de la literaturaO uso da Hidroxicloroquina no decorrer da pandemia da COVID-19: um estudo de revisão bibliográficaCOVID-19SARS-CoV-2Hydroxychloroquine.COVID-19SARS-CoV-2Hidroxicloroquina.COVID-19SARS-CoV-2Hidroxicloroquina.COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19. COVID-19 es una enfermedad infecciosa causada por el SARS-CoV-2, tiene una alta tasa de transmisión y ha provocado miles de muertes registradas en todo el mundo. Actualmente, no hay estudios clínicos que demuestren la efectividad de medicamentos específicos contra el SARS-Cov-2. Sin embargo, experiencias previas con virus similares indicaron una potencial efectividad de ciertos medicamentos, incluido el uso de hidroxicloroquina (HCQ). Al comienzo de la pandemia de COVID-19, la Organización Mundial de la Salud y el Ministerio de Salud del Brazil orientaron el uso de HCQ como opción terapéutica. Sin embargo, se desconocía su papel en la infección viral por SARS-CoV-2, además de sus beneficios reales in vivo. Por lo tanto, el objetivo de este estudio fue realizar una revisión de la literatura sobre el uso de HCQ en casos de COVID-19, y discutir los resultados encontrados en estudios que realizaron pruebas in vitro e in vivo, con el fin de investigar su eficacia terapéutica. La revisión se realizó mediante descriptores en una base de datos informatizada. Varios autores han descrito la eficacia antiviral de la HCQ contra el SARS-CoV-2 in vitro, inhibiendo la replicación del virus y mediando la tormenta de citocinas a través de sus efectos inmunomoduladores. Sin embargo, los análisis in vivo en organismos complejos no mostraron ningún efecto sobre la reducción de la carga viral, así como ningún beneficio clínico para el paciente. Por lo tanto, aunque los resultados preliminares in vitro han demostrado ser positivos y prometedores, la evidencia de los ensayos clínicos aleatorios indicó que el HCQ no causó los mismos efectos in vivo contra COVID-19. A COVID-19 é uma doença infecciosa causada pelo SARS-CoV-2, apresenta elevada taxa de transmissão e têm resultado em milhares de óbitos registrados em todo o mundo. Atualmente, ainda não existem estudos clínicos que comprovem a eficácia de medicamentos específicos contra o SARS-Cov-2. No entanto, experiências anteriores com vírus semelhantes indicaram potencial de efetividade para determinados fármacos, dentre eles, o uso da Hidroxicloroquina (HCQ). No início da pandemia da COVID-19, a Organização Mundial da Saúde e o Ministério da Saúde orientaram a utilização da HCQ como opção terapêutica. No entanto, não se conhecia exatamente o seu papel na infecção viral pelo SARS-CoV-2, além dos seus reais benefícios in vivo. Portanto, o objetivo deste estudo foi realizar uma revisão bibliográfica sobre o uso da HCQ em casos de COVID-19, e discutir os resultados encontrados nos trabalhos que realizaram testes in vitro e in vivo, a fim de investigar a sua eficácia terapêutica. A revisão foi realizada utilizando descritores em base de dados informatizados. A eficácia antiviral da HCQ contra o SARS-CoV-2 in vitro foi descrita por diversos autores, inibindo a replicação do vírus e mediando a tempestade de citocinas por meio de seus efeitos imunomoduladores. No entanto, análises in vivo em organismos complexos não evidenciaram efeito na redução da carga viral, bem como nenhum benefício clínico ao paciente. Desta forma, apesar dos resultados preliminares in vitro terem se mostrado positivos e promissores, as evidências de ensaios clínicos randomizados apontaram que a HCQ não provocou os mesmos efeitos in vivo contra a COVID-19.Research, Society and Development2021-08-15info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1911810.33448/rsd-v10i10.19118Research, Society and Development; Vol. 10 No. 10; e444101019118Research, Society and Development; Vol. 10 Núm. 10; e444101019118Research, Society and Development; v. 10 n. 10; e4441010191182525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/19118/17004Copyright (c) 2021 Amanda Brito Silva; Beatriz Bonfadini de Sá Galbraith; Camila Lopes Rieke Borges; Daniel Pereira de Rezende Sarmento Costa; Danilo Bines; Gabriela Carreiro Kubitschek Lopes; Hannah Barboza Vianna Bekierman; Helena Ferreira Bruzzi Porto; Júlia Moraes de Andrade Seabra; Julia Vieira Santos; Michel Vladimir de Sousa Cabral ; Pedro Henrique Saugo; Victor Gonçalves de Andrade ; Pedro Leite Azevedohttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Amanda BritoGalbraith, Beatriz Bonfadini de Sá Borges, Camila Lopes Rieke Costa, Daniel Pereira de Rezende Sarmento Bines, DaniloLopes, Gabriela Carreiro KubitschekBekierman, Hannah Barboza Vianna Porto, Helena Ferreira Bruzzi Seabra, Júlia Moraes de Andrade Santos, Julia Vieira Cabral , Michel Vladimir de Sousa Saugo, Pedro HenriqueAndrade , Victor Gonçalves de Azevedo, Pedro Leite2021-10-02T21:49:16Zoai:ojs.pkp.sfu.ca:article/19118Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:05.507373Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
El uso de Hidroxicloroquina durante la pandemia de COVID-19: un estudio de revisión de la literatura
O uso da Hidroxicloroquina no decorrer da pandemia da COVID-19: um estudo de revisão bibliográfica
title The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
spellingShingle The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
Silva, Amanda Brito
COVID-19
SARS-CoV-2
Hydroxychloroquine.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
title_short The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
title_full The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
title_fullStr The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
title_full_unstemmed The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
title_sort The use of Hydroxychloroquine during the COVID-19 pandemic: a literature review study
author Silva, Amanda Brito
author_facet Silva, Amanda Brito
Galbraith, Beatriz Bonfadini de Sá
Borges, Camila Lopes Rieke
Costa, Daniel Pereira de Rezende Sarmento
Bines, Danilo
Lopes, Gabriela Carreiro Kubitschek
Bekierman, Hannah Barboza Vianna
Porto, Helena Ferreira Bruzzi
Seabra, Júlia Moraes de Andrade
Santos, Julia Vieira
Cabral , Michel Vladimir de Sousa
Saugo, Pedro Henrique
Andrade , Victor Gonçalves de
Azevedo, Pedro Leite
author_role author
author2 Galbraith, Beatriz Bonfadini de Sá
Borges, Camila Lopes Rieke
Costa, Daniel Pereira de Rezende Sarmento
Bines, Danilo
Lopes, Gabriela Carreiro Kubitschek
Bekierman, Hannah Barboza Vianna
Porto, Helena Ferreira Bruzzi
Seabra, Júlia Moraes de Andrade
Santos, Julia Vieira
Cabral , Michel Vladimir de Sousa
Saugo, Pedro Henrique
Andrade , Victor Gonçalves de
Azevedo, Pedro Leite
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Amanda Brito
Galbraith, Beatriz Bonfadini de Sá
Borges, Camila Lopes Rieke
Costa, Daniel Pereira de Rezende Sarmento
Bines, Danilo
Lopes, Gabriela Carreiro Kubitschek
Bekierman, Hannah Barboza Vianna
Porto, Helena Ferreira Bruzzi
Seabra, Júlia Moraes de Andrade
Santos, Julia Vieira
Cabral , Michel Vladimir de Sousa
Saugo, Pedro Henrique
Andrade , Victor Gonçalves de
Azevedo, Pedro Leite
dc.subject.por.fl_str_mv COVID-19
SARS-CoV-2
Hydroxychloroquine.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
topic COVID-19
SARS-CoV-2
Hydroxychloroquine.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
COVID-19
SARS-CoV-2
Hidroxicloroquina.
description COVID-19 is an infectious disease caused by SARS-CoV-2, has a high transmission rate and has resulted in thousands of registered deaths worldwide. Currently, there are no clinical studies proving the effectiveness of specific drugs against SARS-Cov-2. However, previous experiences with similar viruses indicated potential effectiveness for certain drugs, including the use of Hydroxychloroquine (HCQ). At the beginning of the COVID-19 pandemic, the World Health Organization and the Ministry of Health of Brazil guided the use of HCQ as a therapeutic option. However, its role in viral infection by SARS-CoV-2, in addition to its real benefits in vivo, was unknown. Therefore, the aim of this study was to conduct a literature review on the use of HCQ in cases of COVID-19, and to discuss the results found in studies that performed in vitro and in vivo tests, in order to investigate its therapeutic efficacy. The review was carried out using descriptors in a computerized database. The antiviral efficacy of HCQ against SARS-CoV-2 in vitro has been described by several authors, inhibiting virus replication and mediating cytokine storm through its immunomodulatory effects. However, in vivo analyzes in complex organisms showed no effect on reducing viral load, as well as no clinical benefit to the patient. Thus, although preliminary in vitro results have shown to be positive and promising, evidence from randomized clinical trials indicated that HCQ did not cause the same effects in vivo against COVID-19.
publishDate 2021
dc.date.none.fl_str_mv 2021-08-15
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19118
10.33448/rsd-v10i10.19118
url https://rsdjournal.org/index.php/rsd/article/view/19118
identifier_str_mv 10.33448/rsd-v10i10.19118
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/19118/17004
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 10 No. 10; e444101019118
Research, Society and Development; Vol. 10 Núm. 10; e444101019118
Research, Society and Development; v. 10 n. 10; e444101019118
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052808160083968